These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 21476965

  • 1. Chemokine receptors as specific anti-inflammatory targets in peripheral nerves.
    Ubogu EE.
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):141-53. PubMed ID: 21476965
    [Abstract] [Full Text] [Related]

  • 2. Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists?
    Russo RC, Garcia CC, Teixeira MM.
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):414-27. PubMed ID: 20597027
    [Abstract] [Full Text] [Related]

  • 3. An apparent paradox: chemokine receptor agonists can be used for anti-inflammatory therapy.
    Ali S, O'Boyle G, Mellor P, Kirby JA.
    Mol Immunol; 2007 Mar; 44(7):1477-82. PubMed ID: 17000001
    [Abstract] [Full Text] [Related]

  • 4. Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.
    Dong C, Greathouse KM, Beacham RL, Palladino SP, Helton ES, Ubogu EE.
    Exp Neurol; 2017 Jun; 292():35-45. PubMed ID: 28215575
    [Abstract] [Full Text] [Related]

  • 5. Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.
    Ubogu EE.
    Acta Neuropathol; 2015 Oct; 130(4):445-68. PubMed ID: 26264608
    [Abstract] [Full Text] [Related]

  • 6. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.
    Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodroofe N, Griffin JW, Toyka KV, Ransohoff RM, Hartung HP.
    Brain; 2002 Apr; 125(Pt 4):823-34. PubMed ID: 11912115
    [Abstract] [Full Text] [Related]

  • 7. Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential.
    Jiang BC, Liu T, Gao YJ.
    Pharmacol Ther; 2020 Aug; 212():107581. PubMed ID: 32450191
    [Abstract] [Full Text] [Related]

  • 8. Chemokine receptors: multifaceted therapeutic targets.
    Proudfoot AE.
    Nat Rev Immunol; 2002 Feb; 2(2):106-15. PubMed ID: 11910892
    [Abstract] [Full Text] [Related]

  • 9. Chemokine receptors as therapeutic targets.
    Yoshie O.
    Nihon Rinsho Meneki Gakkai Kaishi; 2013 Feb; 36(4):189-96. PubMed ID: 23994796
    [Abstract] [Full Text] [Related]

  • 10. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system.
    Abbas N, Zou LP, Pelidou SH, Winblad B, Zhu J.
    Autoimmunity; 2000 Sep; 32(2):93-9. PubMed ID: 11078155
    [Abstract] [Full Text] [Related]

  • 11. The chemokine family. Potential therapeutic targets from allergy to HIV infection.
    Proudfoot AE.
    Eur J Dermatol; 1998 Sep; 8(3):147-57. PubMed ID: 9649701
    [Abstract] [Full Text] [Related]

  • 12. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease.
    Donnelly LE, Barnes PJ.
    Trends Pharmacol Sci; 2006 Oct; 27(10):546-53. PubMed ID: 16911834
    [Abstract] [Full Text] [Related]

  • 13. Overcoming hurdles in developing successful drugs targeting chemokine receptors.
    Schall TJ, Proudfoot AE.
    Nat Rev Immunol; 2011 May; 11(5):355-63. PubMed ID: 21494268
    [Abstract] [Full Text] [Related]

  • 14. Targeting the chemokine system for multiple sclerosis treatment.
    Glabinsk AR, Ransohoff RM.
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1712-9. PubMed ID: 11892933
    [Abstract] [Full Text] [Related]

  • 15. The expression and function of chemokines involved in CNS inflammation.
    Ubogu EE, Cossoy MB, Ransohoff RM.
    Trends Pharmacol Sci; 2006 Jan; 27(1):48-55. PubMed ID: 16310865
    [Abstract] [Full Text] [Related]

  • 16. Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking.
    Tomankova T, Kriegova E, Liu M.
    Am J Physiol Lung Cell Mol Physiol; 2015 Apr 01; 308(7):L603-18. PubMed ID: 25637606
    [Abstract] [Full Text] [Related]

  • 17. Chemokine receptors and their antagonists in allergic lung disease.
    Wells TN, Proudfoot AE.
    Inflamm Res; 1999 Jul 01; 48(7):353-62. PubMed ID: 10450784
    [Abstract] [Full Text] [Related]

  • 18. CCR1 chemokine receptor antagonist.
    Saeki T, Naya A.
    Curr Pharm Des; 2003 Jul 01; 9(15):1201-8. PubMed ID: 12769747
    [Abstract] [Full Text] [Related]

  • 19. [Chemokines a hope of specific anti-inflammatory treatment].
    Schedvins P, Hjelmström P.
    Lakartidningen; 2002 Mar 07; 99(10):1056-9. PubMed ID: 12024779
    [Abstract] [Full Text] [Related]

  • 20. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
    Szczuciński A, Losy J.
    Acta Neurol Scand; 2007 Mar 07; 115(3):137-46. PubMed ID: 17295707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.